首都医科大学学报 ›› 2023, Vol. 44 ›› Issue (4): 511-516.doi: 10.3969/j.issn.1006-7795.2023.04.001

• 专家评述 • 上一篇    下一篇

脑胶质瘤新型放射性示踪剂的研究进展

王  凯,  袁磊磊,  陈  谦,  艾  林*   

  1. 首都医科大学附属北京天坛医院核医学科, 北京 100070
  • 收稿日期:2023-06-02 出版日期:2023-08-21 发布日期:2023-07-23
  • 通讯作者: 艾林 E-mail:ailin@bjtth.org

Research progress of new radioactive tracers for cerebral glioma

Wang Kai, Yuan Leilei, Chen Qian, Ai Lin*   

  1. Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing  100070, China
  • Received:2023-06-02 Online:2023-08-21 Published:2023-07-23

摘要: 新型正电子发射断层扫描(positron emission tomography, PET)放射性药物在胶质瘤患者诊断和治疗中具有潜在临床应用价值,除了常用的18F-氟代脱氧葡萄糖和氨基酸类示踪剂外,仍需开发新型PET示踪剂用于研究脑胶质瘤的其他生物特征,包括灌注、血管生成、缺氧、神经炎症、细胞增殖以及肿瘤侵袭性等。目前这些放射性药物仍在进一步探索中,并需要通过临床试验进行验证,以实现其在胶质瘤诊疗评估中的临床转化。

关键词: 胶质瘤, 正电子发射断层扫描, 放射性示踪剂, 18F-氟代脱氧葡萄糖, 氨基酸

Abstract: New positron emission tomography (PET) radiopharmaceuticals have potential clinical application value in the diagnosis and treatment of glioma patients. In addition to commonly used 18F-fluorodeoxyglucose and amino acid tracers, it is still necessary to develop new PET tracers for studying other biological characteristics of glioma, including perfusion, angiogenesis, hypoxia, neuroinflammation, cell proliferation, and tumor invasiveness. At present, these radioactive drugs are still being further explored and need to be validated through clinical trials to achieve their clinical conversion in the diagnosis, treatment, and evaluation of gliomas.

Key words: glioma, positron emission tomography (PET), radioactive tracer, 18F-fluorodeoxyglucose (18F-FDG), amino acid

中图分类号: